首页> 外文期刊>European urology >Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
【24h】

Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.

机译:前列腺癌根治性手术后的癌症特异性死亡率和其他原因的死亡率与前列腺癌患者的观察值:基于北美人群的大型队列的竞争风险分析。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Initial treatment options for low-risk clinically localized prostate cancer (PCa) include radical prostatectomy (RP) or observation. OBJECTIVE: To examine cancer-specific mortality (CSM) after accounting for other-cause mortality (OCM) in PCa patients treated with either RP or observation. DESIGN, SETTING, AND PARTICIPANTS: Using the Surveillance Epidemiology and End Results Medicare-linked database, a total of 44 694 patients >/=65 yr with localized (T1/2) PCa were identified (1992-2005). INTERVENTION: RP and observation. MEASUREMENTS: Propensity-score matching was used to adjust for potential selection biases associated with treatment type. The matched cohort was randomly divided into the development and validation sets. Competing-risks regression models were fitted and a competing-risks nomogram was developed and externally validated. RESULTS AND LIMITATIONS: Overall, 22,244 (49.8%) patients were treated with RP versus 22450 (50.2%) with observation. Propensity score-matched analyses derived 11,669 matched pairs. In the development cohort, the 10-yr CSM rate was 2.8% (2.3-3.5%) for RP versus 5.8% (5.0-6.6%) for observation (absolute risk reduction: 3.0%; relative risk reduction: 0.5%; p<0.001). In multivariable analyses, the CSM hazard ratio for RP was 0.48 (0.38-0.59) relative to observation (p<0.001). The competing-risks nomogram discrimination was 73% and 69% for prediction of CSM and OCM, respectively, in external validation. The nature of observational data may have introduced a selection bias. CONCLUSIONS: On average RP reduces the risk of CSM by half in patients aged >/=65 yr, relative to observation. The individualized protective effect of RP relative to observation may be quantified with our nomogram.
机译:背景:低危临床局限性前列腺癌(PCa)的初始治疗选择包括前列腺癌根治术(RP)或观察。目的:在考虑接受RP或观察治疗的PCa患者的其他原因死亡率(OCM)后,检查癌症特异性死亡率(CSM)。设计,地点和参与者:使用监测流行病学和最终结果与Medicare链接的数据库,总共鉴定出44 694例≥65岁的局部(T1 / 2)PCa患者(1992-2005)。干预:RP和观察。测量:倾向得分匹配用于调整与治疗类型相关的潜在选择偏倚。匹配的队列被随机分为开发和验证集。拟合了竞争风险回归模型,并开发了竞争风险列线图并进行了外部验证。结果与局限性:总体而言,经观察,接受RP治疗的患者为22,244名(49.8%),而经观察为22450(50.2%)的患者。倾向得分匹配分析得出11669个匹配对。在发展队列中,RP的10年CSM率为2.8%(2.3-3.5%),而观察的为5.8%(5.0-6.6%)(绝对风险降低:3.0%;相对风险降低:0.5%; p < 0.001)。在多变量分析中,RP的CSM危险比相对于观察结果为0.48(0.38-0.59)(p <0.001)。在外部验证中,预测CSM和OCM的竞争风险列线图鉴别分别为73%和69%。观测数据的性质可能已经引入了选择偏差。结论:相对于观察,相对于观察,平均RP将年龄≥65岁的患者的CSM风险降低了一半。相对于观察,RP的个性化保护作用可以通过我们的列线图进行量化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号